NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines

David S. Ettinger; Douglas E. Wood; Wallace Akerley; Lyudmila A. Bazhenova; Hossein Borghaei; David Ross Camidge; Richard T. Cheney; Lucian R. Chirieac; Thomas A. D'Amico; Thomas J. Dilling; M. Chris Dobelbower; Ramaswamy Govindan; Mark Hennon; Leora Horn; Thierry M. Jahan; Ritsuko Komaki; Rudy P. Lackner; Michael Lanuti; Rogerio Lilenbaum; Jules Lin; Billy W. Loo; Renato Martins; Gregory A. Otterson; Jyoti D. Patel; Katherine M. Pisters; Karen Reckamp; Gregory J. Riely; Steven E. Schild; Theresa A. Shapiro; Neelesh Sharma; James Stevenson; Scott J. Swanson; Kurt Tauer; Stephen C. Yang; Kristina Gregory; Miranda Hughes

doi:10.6004/jnccn.2016.0031

NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines

David S. Ettinger
, Douglas E. Wood
, Wallace Akerley
, Lyudmila A. Bazhenova
, Hossein Borghaei
, David Ross Camidge
, Richard T. Cheney
, Lucian R. Chirieac
, Thomas A. D'Amico
, Thomas J. Dilling
, M. Chris Dobelbower
, Ramaswamy Govindan
, Mark Hennon
, Leora Horn
, Thierry M. Jahan
, Ritsuko Komaki
, Rudy P. Lackner
, Michael Lanuti
, Rogerio Lilenbaum
, Jules Lin

Billy W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, Miranda Hughes

Johns Hopkins University
Seattle Cancer Care Alliance
University of Utah
University of California at San Diego
University of Colorado Cancer Center
Roswell Park Cancer Institute
Dana-Farber/Brigham and Women's Cancer Center
Duke University
University of South Florida
University of Alabama at Birmingham
Washington University St. Louis
Vanderbilt University
University of California at San Francisco
University of Texas MD Anderson Cancer Center
University of Nebraska Medical Center
Massachusetts General Hospital Cancer Center
Yale University
University of Michigan, Ann Arbor
Stanford University
Ohio State University
Northwestern University
City of Hope National Medical Center
Memorial Sloan-Kettering Cancer Center
Mayo Clinic
Case Western Reserve University
University of Tennessee Health Science Center
National Comprehensive Cancer Network

Research output: Contribution to journal › Review article › peer-review

367 Scopus citations

Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Original language	English
Pages (from-to)	255-264
Number of pages	10
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	14
Issue number	3
DOIs	https://doi.org/10.6004/jnccn.2016.0031
State	Published - Mar 1 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antibodies, Monoclonal, Humanized/adverse effects
Antibodies, Monoclonal/adverse effects
Antineoplastic Agents/adverse effects
Carcinoma, Non-Small-Cell Lung/drug therapy
Carcinoma, Squamous Cell/drug therapy
Docetaxel
Humans
Immunosuppressive Agents/adverse effects
Immunotherapy/methods
Lung Neoplasms/drug therapy
Nivolumab
Practice Guidelines as Topic
Survival Rate
Taxoids/adverse effects

Access to Document

10.6004/jnccn.2016.0031

Cite this

Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., Chris Dobelbower, M., Govindan, R., Hennon, M., Horn, L., Jahan, T. M., Komaki, R., Lackner, R. P., Lanuti, M., Lilenbaum, R., ... Hughes, M. (2016). NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN, 14(3), 255-264. https://doi.org/10.6004/jnccn.2016.0031

@article{4057c273d6a64aba9a41820f32c6926c,

title = "NCCN guidelines{\textregistered} Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines",

abstract = "These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.",

keywords = "Antibodies, Monoclonal, Humanized/adverse effects, Antibodies, Monoclonal/adverse effects, Antineoplastic Agents/adverse effects, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Squamous Cell/drug therapy, Docetaxel, Humans, Immunosuppressive Agents/adverse effects, Immunotherapy/methods, Lung Neoplasms/drug therapy, Nivolumab, Practice Guidelines as Topic, Survival Rate, Taxoids/adverse effects",

author = "Ettinger, \{David S.\} and Wood, \{Douglas E.\} and Wallace Akerley and Bazhenova, \{Lyudmila A.\} and Hossein Borghaei and Camidge, \{David Ross\} and Cheney, \{Richard T.\} and Chirieac, \{Lucian R.\} and D'Amico, \{Thomas A.\} and Dilling, \{Thomas J.\} and \{Chris Dobelbower\}, M. and Ramaswamy Govindan and Mark Hennon and Leora Horn and Jahan, \{Thierry M.\} and Ritsuko Komaki and Lackner, \{Rudy P.\} and Michael Lanuti and Rogerio Lilenbaum and Jules Lin and Loo, \{Billy W.\} and Renato Martins and Otterson, \{Gregory A.\} and Patel, \{Jyoti D.\} and Pisters, \{Katherine M.\} and Karen Reckamp and Riely, \{Gregory J.\} and Schild, \{Steven E.\} and Shapiro, \{Theresa A.\} and Neelesh Sharma and James Stevenson and Swanson, \{Scott J.\} and Kurt Tauer and Yang, \{Stephen C.\} and Kristina Gregory and Miranda Hughes",

note = "Copyright {\textcopyright} 2016 by the National Comprehensive Cancer Network.",

year = "2016",

month = mar,

day = "1",

doi = "10.6004/jnccn.2016.0031",

language = "English",

volume = "14",

pages = "255--264",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Harborside Press",

number = "3",

}

Ettinger, DS, Wood, DE, Akerley, W, Bazhenova, LA, Borghaei, H, Camidge, DR, Cheney, RT, Chirieac, LR, D'Amico, TA, Dilling, TJ, Chris Dobelbower, M, Govindan, R, Hennon, M, Horn, L, Jahan, TM, Komaki, R, Lackner, RP, Lanuti, M, Lilenbaum, R, Lin, J, Loo, BW, Martins, R, Otterson, GA, Patel, JD, Pisters, KM, Reckamp, K, Riely, GJ, Schild, SE, Shapiro, TA, Sharma, N, Stevenson, J, Swanson, SJ, Tauer, K, Yang, SC, Gregory, K & Hughes, M 2016, 'NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 14, no. 3, pp. 255-264. https://doi.org/10.6004/jnccn.2016.0031

TY - JOUR

T1 - NCCN guidelines® Insights

T2 - Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines

AU - Ettinger, David S.

AU - Wood, Douglas E.

AU - Akerley, Wallace

AU - Bazhenova, Lyudmila A.

AU - Borghaei, Hossein

AU - Camidge, David Ross

AU - Cheney, Richard T.

AU - Chirieac, Lucian R.

AU - D'Amico, Thomas A.

AU - Dilling, Thomas J.

AU - Chris Dobelbower, M.

AU - Govindan, Ramaswamy

AU - Hennon, Mark

AU - Horn, Leora

AU - Jahan, Thierry M.

AU - Komaki, Ritsuko

AU - Lackner, Rudy P.

AU - Lanuti, Michael

AU - Lilenbaum, Rogerio

AU - Lin, Jules

AU - Loo, Billy W.

AU - Martins, Renato

AU - Otterson, Gregory A.

AU - Patel, Jyoti D.

AU - Pisters, Katherine M.

AU - Reckamp, Karen

AU - Riely, Gregory J.

AU - Schild, Steven E.

AU - Shapiro, Theresa A.

AU - Sharma, Neelesh

AU - Stevenson, James

AU - Swanson, Scott J.

AU - Tauer, Kurt

AU - Yang, Stephen C.

AU - Gregory, Kristina

AU - Hughes, Miranda

PY - 2016/3/1

Y1 - 2016/3/1

N2 - These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

AB - These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

KW - Antibodies, Monoclonal, Humanized/adverse effects

KW - Antibodies, Monoclonal/adverse effects

KW - Antineoplastic Agents/adverse effects

KW - Carcinoma, Non-Small-Cell Lung/drug therapy

KW - Carcinoma, Squamous Cell/drug therapy

KW - Docetaxel

KW - Humans

KW - Immunosuppressive Agents/adverse effects

KW - Immunotherapy/methods

KW - Lung Neoplasms/drug therapy

KW - Nivolumab

KW - Practice Guidelines as Topic

KW - Survival Rate

KW - Taxoids/adverse effects

UR - https://www.scopus.com/pages/publications/84961575658

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000371997900006&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.6004/jnccn.2016.0031

DO - 10.6004/jnccn.2016.0031

M3 - Review article

C2 - 26957612

SN - 1540-1405

VL - 14

SP - 255

EP - 264

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 3

ER -

NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this